Corcept Therapeutics (CORT) EBT Margin (2016 - 2025)
Historic EBT Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 7.34%.
- Corcept Therapeutics' EBT Margin fell 216600.0% to 7.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.94%, marking a year-over-year decrease of 145200.0%. This contributed to the annual value of 23.92% for FY2024, which is 19000.0% down from last year.
- According to the latest figures from Q3 2025, Corcept Therapeutics' EBT Margin is 7.34%, which was down 216600.0% from 16.3% recorded in Q2 2025.
- Corcept Therapeutics' 5-year EBT Margin high stood at 37.77% for Q3 2021, and its period low was 6.12% during Q1 2025.
- Moreover, its 5-year median value for EBT Margin was 27.18% (2023), whereas its average is 25.17%.
- In the last 5 years, Corcept Therapeutics' EBT Margin surged by 84100bps in 2021 and then tumbled by -216600bps in 2025.
- Corcept Therapeutics' EBT Margin (Quarter) stood at 37.17% in 2021, then crashed by -37bps to 23.56% in 2022, then grew by 15bps to 27.18% in 2023, then crashed by -35bps to 17.57% in 2024, then crashed by -58bps to 7.34% in 2025.
- Its last three reported values are 7.34% in Q3 2025, 16.3% for Q2 2025, and 6.12% during Q1 2025.